DS
AMRX icon

David Shaw’s Amneal Pharmaceuticals AMRX Stock Holding History

David Shaw’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Sell
774,055
-945,899
-55% -$13M 0.01% 1590
2026
Q1 		$21.4M Sell
1,719,954
-941,900
-35% -$12.6M 0.01% 1099
2025
Q4 		$33.5M Buy
2,661,854
+1,096,643
+70% +$12.5M 0.02% 931
2025
Q3 		$15.7M Buy
1,565,211
+641,567
+69% +$5.76M 0.01% 1347
2025
Q2 		$7.47M Buy
923,644
+907,808
+5,733% +$6.84M 0.01% 1723
2025
Q1 		$133K Buy
+15,836
New +$132K ﹤0.01% 3990
2024
Q3 		– Sell
-89,895
Closed -$571K – 4510
2024
Q2 		$571K Sell
89,895
-136,309
-60% -$865K ﹤0.01% 3544
2024
Q1 		$1.37M Sell
226,204
-439,832
-66% -$2.48M ﹤0.01% 2892
2023
Q4 		$4.04M Sell
666,036
-208,880
-24% -$930K ﹤0.01% 2081
2023
Q3 		$3.69M Buy
874,916
+252,690
+41% +$942K ﹤0.01% 2088
2023
Q2 		$1.93M Sell
622,226
-7,883
-1% -$16.8K ﹤0.01% 2650
2023
Q1 		$876K Sell
630,109
-58,728
-9% -$117K ﹤0.01% 3246
2022
Q4 		$1.37M Buy
688,837
+427,987
+164% +$959K ﹤0.01% 3223
2022
Q3 		$527K Buy
260,850
+71,923
+38% +$202K ﹤0.01% 4013
2022
Q2 		$601K Sell
188,927
-65,072
-26% -$236K ﹤0.01% 3994
2022
Q1 		$1.06M Buy
253,999
+95,977
+61% +$425K ﹤0.01% 3868
2021
Q4 		$757K Buy
158,022
+139,980
+776% +$698K ﹤0.01% 4143
2021
Q3 		$96K Buy
+18,042
New +$90.8K ﹤0.01% 4721
2021
Q2 		– Sell
-122,774
Closed -$826K – 4733
2021
Q1 		$826K Buy
+122,774
New +$680K ﹤0.01% 3243
2020
Q1 		– Sell
-224,285
Closed -$1.08M – 3898
2019
Q4 		$1.08M Buy
224,285
+125,081
+126% +$435K ﹤0.01% 2928
2019
Q3 		$288K Sell
99,204
-59,475
-37% -$208K ﹤0.01% 3486
2019
Q2 		$1.14M Sell
158,679
-265,301
-63% -$2.71M ﹤0.01% 2601
2019
Q1 		$6.01M Sell
423,980
-378,882
-47% -$5.01M 0.01% 1430
2018
Q4 		$10.9M Buy
802,862
+56,890
+8% +$1.03M 0.02% 1037
2018
Q3 		$16.6M Sell
745,972
-246,020
-25% -$5.18M 0.02% 864
2018
Q2 		$16.3M Buy
+991,992
New +$17.4M 0.02% 836

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's AMRX Position: Q2 2026 in Review

David Shaw reduced its Amneal Pharmaceuticals (AMRX) stake by 55% in Q2 2026, selling an estimated $13M and leaving 774,055 shares worth $13.4M. The position accounts for 0.01% of the portfolio, ranked #1590.

David Shaw first reported a position in AMRX in Q2 2018 and has held it in 26 quarters since. The position peaked at $33.5M in Q4 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • David Shaw held 774,055 shares of Amneal Pharmaceuticals worth $13.4M as of Q2 2026.
  • David Shaw sold 945,899 Amneal Pharmaceuticals shares in Q2 2026, an estimated $13M.
  • Amneal Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1590 holding.
  • David Shaw first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 26 quarters since.
  • David Shaw's Amneal Pharmaceuticals position peaked at $33.5M in Q4 2025.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.